From the Practice
Evidence-based commentary on interventional psychiatry, ketamine therapy, Spravato, PTSD treatment, and related clinical topics.
Medically reviewed by Dr. Lisa Parker, DNP, APRN, NP | Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Here’s the honest answer up front: ketamine is a promising, but still emerging, option for obsessive-compulsive disorder that hasn’t responded to standard treatment. Early research shows it can reduce obsessive thoughts quickly for some people, but the […]
If you’re partway through Spravato or IV ketamine treatment and need to change clinics, whether your clinic is closing, you’ve moved, your insurance changed, or it simply isn’t the right fit anymore, the most important thing to know is this: transferring care is a normal, manageable process, and your progress doesn’t disappear when your provider […]
Medically reviewed by Dr. Lisa Parker, DNP, APRN, NP — Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Millions of people fill a prescription, take it exactly as directed, and keep waiting to feel like themselves again. For a large share of them, that feeling doesn’t come, or it arrives as a kind of numbness […]
Medically reviewed by Dr. Lisa Parker, DNP, APRN, NP — Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Imagine standing at a locked door, putting a key in, turning it, and nothing happens. Nobody concludes they’re simply bad at opening doors. They realize they need a different key. That same logic applies to depression treatment […]
By Dr. Lisa Parker, DNP, APRN, NP — Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Here is the direct answer: ketamine and Spravato® therapy for treatment-resistant depression is outpatient care. That is not a limitation of my practice, and it is not something I work around. It is how this treatment is built to […]
Lisa Parker, DNP, APRN, NP Founder, Parker Neuroscience, LLC | Omaha, Nebraska Most of what gets written about IV ketamine focuses on two questions: does it work, and is it medically safe. Both matter, and the answers are encouraging. A systematic review of 93 clinical trials found that among 3,756 participants who received at least […]
Here’s the direct answer: at Parker Neuroscience, IV ketamine, not Spravato, is the option used off-label for anxiety. Spravato’s FDA approval is specific to treatment-resistant depression and MDD with acute suicidal ideation, not anxiety on its own. IV ketamine works through a different pathway than most anxiety medications, targeting the brain’s glutamate system rather than […]
If you’re weighing IV ketamine against Spravato, here’s the short answer: there isn’t a single treatment that’s better for everyone. Spravato is FDA-approved for treatment-resistant depression and MDD with acute suicidal ideation, administered as a nasal spray under a certified REMS monitoring protocol. IV ketamine is administered intravenously and used off-label for treatment-resistant depression, PTSD, […]
By Dr. Lisa Parker, DNP, APRN, NP — Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Why does ketamine seem to help some people dramatically while others don’t experience the same results? Patients ask me this regularly, and it deserves an honest answer rather than a sales answer. So here it is: mental health treatment […]
By Dr. Lisa Parker, DNP, APRN, NP — Owner & Clinical Director, Parker Neuroscience, Omaha, Nebraska Many patients tell me their biggest fear about ketamine therapy is not the treatment itself. It’s simply not knowing what to expect. That fear makes sense. Most people considering this treatment have never seen the inside of an interventional […]
